

1 **Mechanisms of Ranolazine Pretreatment in Preventing Ventricular Tachyarrhythmias**  
2 **in Diabetic *db/db* Mice with Acute Regional Ischemia-Reperfusion Injury**

3 Chung-Chuan Chou, MD;<sup>1,6</sup> Hui-Ling Lee, MD;<sup>4</sup> Gwo-Jyh Chang, PhD;<sup>5,6</sup> Hung-Ta Wo,  
4 MD;<sup>1</sup> Tzung-Hai Yen, MD;<sup>2,6</sup> Ming-Shien Wen, MD;<sup>1,6</sup> Yen Chu, DSc;<sup>3,6</sup> Hao-Tien Liu, MD;<sup>1</sup>  
5 Po-Cheng Chang, MD<sup>1,6</sup>

6 <sup>1</sup>Division of Cardiology, and <sup>2</sup>Division of Nephrology, Department of Internal Medicine, and  
7 <sup>3</sup>Department of Thoracic Surgery, Chang Gung Memorial Hospital, Linkou; <sup>4</sup>Department of  
8 Anesthesia, Chang Gung Memorial Hospital, Taipei; <sup>5</sup>Graduate Institute of Clinical Medicine,  
9 <sup>6</sup>Chang Gung University College of Medicine, Taoyuan; Taiwan.

10

11

**Supplementary Methods**

12 This study protocol was approved by the Institutional Animal Care and Use Committee of  
13 Chang Gung Memorial Hospital (approval No. 2015092401) and conformed to the Guide for  
14 the Care and Use of Laboratory Animals published by the United States National Institutes of  
15 Health. Mice were divided into 4 groups: diabetic mice not given ranolazine (*db/db* C, n=22,  
16 12 female, age  $23.7 \pm 3.6$  weeks, body weight  $55.0 \pm 7.8$  g), diabetic mice given ranolazine  
17 (*db/db* R, n=21, 11 female, age  $23.7 \pm 5.5$  weeks, body weight  $59.6 \pm 12.0$  g), control mice  
18 not given ranolazine (*db/+* C, n=23, 11 female, age  $23.2 \pm 3.5$  weeks, body weight  $30.1 \pm 3.9$   
19 g), and control mice given ranolazine (*db/+* R, n=21, 10 female, age  $24.7 \pm 2.9$  weeks, body  
20 weight  $31.9 \pm 4.2$  g). Mice were raised in vivarium under standard conditions at a constant  
21 temperature ( $22 \pm 1$  °C), lights on from 8:00 to 20:00, and food and water available ad  
22 libitum. Ranolazine (R6152; Sigma-Aldrich, Munich, Germany) was administered orally 305  
23 mg/kg/day (dose comparable with that used clinically in humans of 750 mg twice daily)<sup>1</sup> for  
24 7 days in the ranolazine-given groups.

## 1 **In-vivo IR model creation and electrophysiological studies**

2 Mice were pre-medicated with xylazine (10 mg/kg intraperitoneally) and zoletil (25 mg/kg  
3 intraperitoneally), then intubated and anesthetized with isoflurane using a mouse ventilator  
4 (Harvard Apparatus, MA, USA). When the mice were fully anesthetized and unresponsive to  
5 physical stimuli, the chests were opened via a median thoracotomy to expose the heart.  
6 Regional myocardial ischemia was created using a 7-0 non-absorbable prolene suture line to  
7 ligate the left coronary artery at the midway between the atrio-ventricular junction and the  
8 apex. Ischemia was confirmed by the appearance of hypokinesis and pallor distal to the  
9 occlusion. After 15 minutes of ischemia, the ligature was removed, and reperfusion was  
10 visually confirmed (Figure 5A).

11 In vivo electrophysiological study was performed using the same method previously  
12 described.<sup>2</sup> Platinum electrodes were inserted into the limbs and three-lead  
13 pseudo-electrocardiogram was obtained with Axon Digidata (Molecular Devices, CA, USA).  
14 A custom-made bipolar electrode was placed on the ventricular epicardium for ventricular  
15 pacing at twice the threshold. Extrastimulus pacing ( $S_1$ - $S_4$ ) and burst pacing (pacing cycle  
16 length (PCL) = 50 ms, 2 sec) were used to test VT ( $\geq$  three consecutive premature ventricular  
17 beats) inducibility to all mice. We first measured effective refractory period by giving a  
18 premature stimulus after 8 beats of  $S_1S_1$  pacing at a PCL of 200 ms. The extrastimulus pacing  
19 represents a fixed  $S_1S_1$  PCL of 200 ms for 8 beats, followed by extrastimuli from 80 ms in 10  
20 ms decrements. The  $S_1$ - $S_2$  and  $S_2$ - $S_3$  intervals were reduced with either the  $S_1$ - $S_2$  being long  
21 and  $S_2$ - $S_3$  being short or vice versa, or be decreased simultaneously. The  $S_3$ - $S_4$  interval was  
22 shortened until loss of ventricular capture or induction of VT. The severity of inducible VT  
23 was classified as  $< 10$  beats, between 10 to 30 sec, and  $> 30$  beats.

24

## 1 **Western blotting**

2 Cardiac tissues were sampled from the non-IR and IR zones of the mapped anterior aspect of  
3 left ventricle at the end of in vivo electrophysiological studies for protein quantification as  
4 previously described (n = 6 per group).<sup>3</sup> Briefly, 50 µg of protein was loaded to each well in  
5 the SDS-PAGE gel for electrophoresis. The sample was then transferred onto a  
6 polyvinylidene difluoride membrane (PVDF, Immobilon-P, EMD millipore, Temecula, CA,  
7 USA). Primary antibodies against SERCA2a (Thermo, USA), CaMKIIδ (Cell Signaling,  
8 USA), pThr<sup>287</sup>-CaMKIIδ (CaMKIIδ-p, Thermo, USA), PLB (phospholamban, Cell Signaling,  
9 USA), pSer<sup>16</sup>-phospholamban (PLB-S, Gene Tex, USA), pThr<sup>17</sup>-PLN (PLB-T, Badrilla, UK),  
10 dihydropyridine receptor (DHP1α, Abcam, Cambridge, UK), Na<sup>+</sup>-Ca<sup>2+</sup> exchanger (NCX,  
11 Abcam, Cambridge, UK), calsequestrin 2 (CASQ2) (Gene Tex, USA), Nav1.5 (SCN5A)  
12 (Alomone, USA), connexin43 (Cx43, Gene Tex, USA), and GAPDH (Santa Cruz, USA)  
13 were used to detect the proteins of interest. Secondary antibodies, such as goat anti-mouse  
14 IgG-HRP (Leinco Technologies, USA), goat anti-rabbit IgG-HRP (Leinco Technologies,  
15 USA) and donkey anti-goat IgG-HRP antibody (Santa Cruz, USA), were used in conjunction  
16 with primary antibodies. Signals were obtained through enhanced chemiluminescence (Pierce  
17 ECL Western Blotting Substrate, Thermo, USA) and blots were quantified through scanning  
18 densitometry. The levels of protein expression were normalized to that of GAPDH. We  
19 performed several scans with different exposure, and Figure S3-3 shows an example of the  
20 PLB gels with different exposure.

21

## 22 **Langendorff heart preparation and optical mapping studies**

23 Details of the experimental procedure for dual optical mapping of membrane voltage ( $V_m$ )  
24 and  $Ca_i$  transients have been previously described.<sup>4</sup> In brief, the hearts were excised after

1 reperfusion for 10 min, Langendorff-perfused and loaded with Rhod-2AM ( $\text{Ca}_i$  indicator) and  
2 RH237 ( $\text{V}_m$  indicator). Motion artifacts were suppressed using 15  $\mu\text{M}$  blebbistatin (Tocris  
3 Bioscience, MN, USA). The hearts were illuminated using a solid-state, frequency-doubled  
4 laser light source (Millennia, Spectra-Physics Inc., CA, USA) with a wavelength of 532 nm.  
5 Epifluorescence was acquired simultaneously through two high-speed cameras (MiCAM  
6 Ultima, BrainVision, Tokyo, Japan) at 1 ms/frame through a  $580 \pm 20\text{-nm}$  bandpass filter and  
7 a 715-nm long-pass filter for  $\text{Ca}_i$  and  $\text{V}_m$  images, respectively. Digital images ( $100 \times 100$   
8 pixels) were gathered from a mapped field of  $14 \times 14 \text{ mm}^2$ , resulting in a spatial resolution of  
9  $140 \times 140 \mu\text{m}^2$  per pixel. A bipolar lead was used to pace the lateral wall of the left ventricle at  
10 a double threshold. The effective refractory period (ERP) was measured by giving a  
11 premature stimulus after 8 beats at a 200-ms PCL. Action potential duration ( $\text{APD}$ )<sub>80</sub> (APD at  
12 80% repolarization) and  $\text{Ca}_i$  alternans were induced and conduction velocity (CV) were  
13 studied by a dynamic pacing protocol.<sup>4</sup> VA inducibility was defined as the ability to provoke  
14 VT/VF with the dynamic pacing protocol and/or programmed extra stimuli (up to  $\text{S}_4$ ).

15

## 16 **Cardiomyocyte isolation and whole-cell patch clamp**

17 Cardiomyocytes from left ventricular non-IR and IR zones were isolated using a modified  
18 enzymatic digestion protocol.<sup>5</sup> Following the IR injury, the mouse hearts were harvested and  
19 Langendorff-perfused for 10 minutes with  $I_{\text{Na}}$  bath solution. The composition of the  $I_{\text{Na}}$  bath  
20 solution consisted of (in mmol/L) NaCl, 137; KCl, 5.4;  $\text{MgSO}_4$ , 1.22;  $\text{NaH}_2\text{PO}_4$ , 1.2; HEPES,  
21 6; D-glucose, 22; and  $\text{CaCl}_2$ , 1.8 (pH 7.4 with NaOH). The hearts were then perfused with  
22  $\text{Ca}^{2+}$ -free  $I_{\text{Na}}$  bath solution for another 10 minutes. The hearts were then digested with the  
23 same  $I_{\text{Na}}$  bath solution containing 150 U/mL type II collagenase (Worthington, Lakewood, NJ,  
24 USA) for 30 minutes. After the enzymatic digestion, the hearts were removed from the  
25 perfusion system. Tissues from the left ventricular IR and non-IR zones were cut into small

1 pieces and dissected mechanically to obtain isolated cardiomyocytes. All enzymatic isolation  
2 procedures were performed at 37°C. During the procedure, the hearts were maintained at a  
3 perfusion pressure at 80 cmH<sub>2</sub>O.

4 Whole-cell mode of the patch-clamp technique was used to measure late  $I_{Na}$  as described  
5 previously.<sup>6</sup> All experiments were conducted at room temperature. An Axopatch 200B  
6 amplifier was used to generate pulse protocols. A software pCLAMP 8 (Molecular  
7 Device/Axon, Sunnyvale, CA, USA) was used to record data. Borosilicate glass capillaries  
8 (WPI Inc., Sarasota, FL, USA) were used to make pipette electrodes with a resistance of 3–5  
9 MΩ in the bath solution. The pipette solution contained (in mmol/L): CsCl, 130; TEA-Cl, 15;  
10 HEPES, 10; D-glucose, 5 and EGTA, 5 (pH 7.4 with CsOH). Current traces were analyzed  
11 using Clampfit- 8 (Molecular Devices/Axon). Whole-cell configuration was performed in  
12 Ca<sup>2+</sup>-free  $I_{Na}$  bath solution (with additional 2 mmol/L CsCl), and capacitance currents were  
13 monitored with a repetitive 5-mV step pulse for at least 5 minutes. Whole cell currents were  
14 elicited by a 300-ms depolarizing pulse from a holding potential of -80 to 30 mV at a  
15 frequency of 0.2 Hz in the ventricular myocytes. The amplitude of late  $I_{Na}$  was measured at  
16 200 ms after a depolarizing pulse to eliminate the effect of transient sodium current. Current  
17 density was calculated by dividing the amplitude by the cell capacitance. All chemicals were  
18 purchased from Sigma unless otherwise stated (Sigma, St. Louis, MO, USA).

19

## 20 **Data analysis**

21 APD<sub>80</sub> and Ca<sub>i</sub> transient duration (Ca<sub>i</sub>TD<sub>80</sub>) were measured at PCLs of 200 and 100 ms using  
22 the same method as previously described.<sup>2</sup> We used monoexponential fittings to compute the  
23 time constant ( $\tau$ ) of the decay portion of the Ca<sub>i</sub> transient between 70% of the transient peak  
24 and the diastolic baseline. The thresholds of APD<sub>80</sub> and Ca<sub>i</sub> alternans were defined as the

1 longest PCL required to produce a 4-ms difference in  $APD_{80}$  and a 10% difference in  $Ca_i$   
2 amplitude between consecutive beats, respectively. The phase was considered positive for a  
3 short-long APD and a small-large  $Ca_i$  amplitude sequence (color coded in red) and was  
4 negative for a long-short APD and a large-small  $Ca_i$  amplitude sequence (color coded in  
5 green). Spatially discordant alternans (SDA) was evidenced by the presence of both red and  
6 green regions separated by a nodal line. To estimate CV, we measured the distance and  
7 conduction time between the earliest activation point and two epicardial points: one was from  
8 the pacing site to the LV apex ( $CV_{IR}$ ), and the other was along an axis parallel to the  
9 atrioventricular ring ( $CV_{non-IR}$ ) (Figure 4B, right subpanels).<sup>7</sup>

## References

- 1  
2 **1.** Tocchetti CG, Carpi A, Coppola C, Quintavalle C, Rea D, Campesan M, Arcari A,  
3 Piscopo G, Cipresso C, Monti MG. Ranolazine protects from doxorubicin- induced  
4 oxidative stress and cardiac dysfunction. *European journal of heart failure*  
5 2014;16:358-366.
- 6 **2.** Chou CC, Ho CT, Lee HL, Chu Y, Yen TH, Wen MS, Lin SF, Lee CH, Chang PC.  
7 Roles of impaired intracellular calcium cycling in arrhythmogenicity of diabetic  
8 mouse model. *Pacing and Clinical Electrophysiology* 2017;40:1087-1095.
- 9 **3.** Chang PC, Huang YC, Lee HL, Chang GJ, Chu Y, Wen MS, Chou CC.  
10 Inhomogeneous Down- regulation of INa underlies piceatannol pro- arrhythmic  
11 Mechanism in regional ischemia- reperfusion. *Pacing and Clinical Electrophysiology*  
12 September 2018 2018;41:1116-1122.
- 13 **4.** Chou CC, Chang PC, Wei YC, Lee KY. Optical mapping approaches on muscleblind-  
14 like compound knockout mice for understanding mechanistic insights into ventricular  
15 arrhythmias in myotonic dystrophy. *Journal of the American Heart Association*  
16 2017;6:e005191.
- 17 **5.** Chang PC, Turker I, Lopshire JC, Masroor S, Nguyen BL, Tao W, Rubart M, Chen PS,  
18 Chen Z, Ai T. Heterogeneous upregulation of apamin- sensitive potassium currents in  
19 failing human ventricles. *Journal of the American Heart Association* 2013;2:e004713.
- 20 **6.** Chang G-J, Chang C-J, Chen W-J, Yeh Y-H, Lee H-Y. Electrophysiological and  
21 mechanical effects of caffeic acid phenethyl ester, a novel cardioprotective agent with  
22 antiarrhythmic activity, in guinea-pig heart. *European journal of pharmacology*  
23 2013;702:194-207.
- 24 **7.** Chou C-C, Chang P-C, Wen M-S, Lee H-L, Wo H-T, Yeh S-J, Wu D. Piceatannol


1 facilitates conduction block and ventricular fibrillation induction in  
2 ischemia-reperfused rabbit hearts with pacing-induced heart failure. International  
3 journal of cardiology 2014;171:250-258.

4

5




1 **Supplementary Figure S1**



3 **Supplementary Figure S1** Representative examples of membrane voltage ( $V_m$ ) and  
4 intracellular  $Ca^{2+}$  ( $Ca_i$ ) alternans maps in the four study groups. Spatially discordant alternans  
5 (SDA) was induced by shortening pacing cycle length (PCL). Ranolazine increased the  
6 pacing threshold of SDA induction. Red arrows indicate the nodal lines.

7

1 **Supplementary Figure S2**



2

3 **Supplementary Figure S2** Representative examples of Western blotting results. Panels show

4 representative bands (A) and histograms represent densitometric values normalized to the

5 corresponding GAPDH (B). Values are means, with their standard errors represented by

6 vertical bars.


7

8


1 Supplementary Figure S3-1

	<i>db/db</i> R		<i>db/db</i> C		<i>db/+</i> R		<i>db/+</i> C	
	Non-IR	IR	Non-IR	IR	Non-IR	IR	Non-IR	IR
No	1	2	3	4	5	6	7	8


DHP1 $\alpha$ (200 kDa)



NCX(120 kDa)



SERCA(110 kDa)




2

3


1 **Supplementary Figure S3-2**

	<b><i>db/db</i> R</b>		<b><i>db/db</i> C</b>		<b><i>db/+</i> R</b>		<b><i>db/+</i> C</b>	
	Non-IR	IR	Non-IR	IR	Non-IR	IR	Non-IR	IR
No	1	2	3	4	5	6	7	8


CAMK (50 kDa)



CAMK-P (50 kDa)



CX43 (43 kDa)





2

3


1 Supplementary Figure S3-3

	<i>db/db</i> R		<i>db/db</i> C		<i>db/+</i> R		<i>db/+</i> C	
	Non-IR	IR	Non-IR	IR	Non-IR	IR	Non-IR	IR
No	1	2	3	4	5	6	7	8

PLN (30 kDa)



PLN-S (25 kDa)




2

3


1 Supplementary Figure S3-4

	<i>db/db</i> R		<i>db/db</i> C		<i>db/+</i> R		<i>db/+</i> C	
	Non-IR	IR	Non-IR	IR	Non-IR	IR	Non-IR	IR
No	1	2	3	4	5	6	7	8


PLN-P (25 kDa)



CASQZ(46 kDa)



SCN5A(228 kDa)






2

3

1 Supplementary Figure S3-5

	<b><i>db/db</i> R</b>		<b><i>db/db</i> C</b>		<b><i>db/+</i> R</b>		<b><i>db/+</i> C</b>	
	Non-IR	IR	Non-IR	IR	Non-IR	IR	Non-IR	IR
No	1	2	3	4	5	6	7	8

GAPDH (36 kDa)



2

3

- 1 **Supplementary Figure S3.** Representative examples of the original gel of the Western
- 2 blotting. Grouping and the corresponding serial numbers were displayed in each cropped gel.
- 3 All the illustrations were acquired from the original gels without editing. Figure S3-3 shows
- 4 examples of PLB bands with 5-sec (adequate) exposure and 1-sec exposure.